查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2008678

纤维肌痛治疗市场：按药物类别、给药途径、分销管道和最终用户分類的全球市场预测 – 2026-2032 年

Fibromyalgia Therapeutics Market by Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，纤维肌痛治疗市场价值将达到 38.5 亿美元，到 2026 年将成长至 40.4 亿美元，到 2032 年将达到 56.6 亿美元，复合年增长率为 5.66%。

主要市场统计数据
基准年 2025 38.5亿美元
预计年份：2026年 40.4亿美元
预测年份 2032 56.6亿美元
复合年增长率 (%) 5.66%

详细介绍不断发展的纤维肌痛治疗市场，重点关注临床复杂性、治疗差距和策略重点。

纤维肌痛症是一种临床表现复杂的综合征，其特征是慢性、广泛性疼痛、疲劳、睡眠障碍和认知症状，这些症状共同导致患者功能显着受损，并给医疗保健系统带来沉重负担。临床异质性和重迭的合併症（例如情绪障碍和慢性疼痛综合症）使诊断和治疗方法选择更加复杂，凸显了个体化治疗路径和多方面管理策略的重要性。在临床实践中，临床医生需要在药物治疗和非药物治疗之间取得平衡，以缓解症状，同时最大限度地降低副作用和多重用药的风险。

变革性的变化正在重塑纤维肌痛的治疗，其手段包括以机制为中心的治疗方法、数位化护理、适应性临床试验以及与保险公司不断发展的合作。

近年来，一系列变革性的变化正在改变我们开发、评估和提供纤维肌痛治疗的方式。科学进步正将治疗重点从广泛的症状治疗转向基于神经生物学、针对特定通路的干预措施，同时，适应性试验设计和精细的受试者选择策略正在加速我们在临床相关人群中检验基于机制的假设。同时，数位疗法和远端监测工具的兴起正在扩大非药物治疗的选择范围，这些选择可以与药物治疗相结合，从而提供全面的护理。

本研究评估了 2025 年美国关税措施将如何影响纤维肌痛治疗的供应链、采购决策和发展策略。

政策干预，例如关税调整，会对与治疗药物的研发和上市相关的营运和策略决策产生重大影响。美国2025年实施的关税措施将成为纤维肌痛治疗生态系中相关人员关注的关键因素。这些措施将影响活性成分、特殊辅料、用于神经调控和药物输送的医疗设备以及生物标记检测所需的实验室试剂的成本和供应。因此，申办方和生产商需要重新审视筹资策略和库存管理实践，以应对供应链波动风险。

深入了解药物类别趋势、给药途径、分销管道和最终用户细分，有助于指导临床和商业决策。

透过細項分析获得的洞见揭示了临床、商业性和营运选择如何在定义纤维肌痛治疗生态系统的多个维度上相互交织。药物类别包括抗惊厥药、选择性血清素再回收抑制剂（SSRIs）、血清素-正肾上腺素再回收抑制剂（SNRIs）和三环抗忧郁药物。在这些类别中，抗惊厥药又可进一步细分为品牌药和选择性血清素再回收抑制剂学名药两种选择，类似的品牌药与学名药的动态也适用于SSRIs、 血清素-正肾上腺素和三环抗忧郁药物，这直接影响着药物的生命週期规划和价格竞争力。

针对全球纤维肌痛治疗的管理体制、临床应用、报销模式和业务重点，提供区域性见解。

区域趋势对纤维肌痛治疗的发展重点、进入策略和商业化路径有显着影响，因此，采取因地制宜的方法至关重要。在美洲，法规结构和与支付方的谈判中都强调疗效和药物经济评估，而创新中心和成熟的契约製造网络则有助于快速改进产品并增强供应链的韧性。此外，美洲地区数位医疗解决方案的普及和病患支援活动的开展都在不断推进，这有望加快分散式临床试验的受试者招募和整合式照护路径的实施。

对创新者、专业开发公司、契约製造和数位供应商如何塑造纤维肌痛护理策略进行企业和竞争考察。

纤维肌痛治疗领域企业的定位反映了创新主导研发公司、专业生物技术企业、契约製造和新兴数位医疗供应商之间的互动。创新者专注于独特的作用机制和更高的耐受性，以实现临床差异化；而专业研发公司和平台公司则致力于探索可与药物疗法相结合的辅助疗法，以应对纤维肌痛症状带来的多重负担。契约製造和CDMO在确保复杂製剂的大规模生产和供应的可靠性方面发挥着核心作用，其能力在合作伙伴选择和紧急时应对计画中也变得日益重要。

为产业领导者提供切实可行的建议，以优先考虑供应链韧性、循证开发、支付方合作以及以患者为中心的商业化方法。

产业领导者应采取多管齐下的方法，增强供应链韧性，推动实证实践，并将病患体验置于商业化计画的核心。首先，透过多元化关键原料药和组件的供应商基础、投资策略库存缓衝以及定期进行供应商风险评估来强化供应链，从而预测采购中断情况。其次，优先考虑整合患者报告结局（PRO）和功能性终点的研发项目，在适当情况下采用适应性或富集性试验设计，并儘早与监管机构和支付方开展对话，以就可接受的证据包达成共识。

详细的调查方法解释了应用于纤维肌痛研究结果的数据来源、专家参与、真实世界数据 (REW) 方法以及分析的严谨性。

为支持这些发现，本研究采用了一种混合方法，将定性专家意见与定量证据来源和文献分析相结合，以确保分析的严谨性和有效性。主要研究包括对临床关键意见领袖、处方集决策者、采购专家以及在纤维肌痛领域开展专案的开发人员进行结构化访谈，从而观点真实世界的治疗模式、证据预期和运营限制。次要资讯包括同行评审的临床文献、监管申报文件、临床试验註册资讯以及公开的临床和安全资料储存库，从而对作用机制和疗效讯号进行背景分析。

总结整合，强调将临床、商业性和政策措施整合起来，以加速显着改善纤维肌痛患者的照护结果。

总之，纤维肌痛的治疗正处于一个转折点，其特征是对疾病机制有了更深入的了解，对证据的期望发生了转变，以及受政策和供应方面因素影响而导致的运营环境变化。有效的应对措施需要将治疗方案的发展与以患者为中心的终点指标相结合，投资于互补的数位化和行为疗法解决方案，并保持供应链的灵活性以应对政策变化。临床医生、保险公司和研发人员必须通力合作，共同製定有意义的疗效指标，并制定能够获得监管部门核准和保险公司认可的实证方案。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 纤维肌痛治疗市场：依药物类别划分

  • 抗惊厥药物
    • 品牌商品
    • 非专利的
  • 选择性血清素再回收抑制剂
    • 品牌商品
    • 非专利的
  • 血清素-正肾上腺素再回收抑制剂
    • 品牌商品
    • 非专利的
  • 三环抗忧郁药物
    • 品牌商品
    • 非专利的

第九章：纤维肌痛治疗市场：依给药途径划分

  • 口服
  • 肠外
  • 外用

第十章：纤维肌痛治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十一章 纤维肌痛治疗市场：依最终使用者划分

  • 居家照护
  • 医院
  • 专科诊所

第十二章 纤维肌痛治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 纤维肌痛治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 纤维肌痛治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国纤维肌痛治疗市场

第十六章：中国纤维肌痛治疗药物市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Amicus Therapeutics
  • Astellas Pharma Inc
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc
  • CH Boehringer Sohn AG & Co. KG
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline（GSK）
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin Co, Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries Ltd.
  • The Bristol-Myers Squibb Company
  • Vertex Pharmaceuticals Incorporated
  • Viatris inc.
Product Code: MRR-8E22B61932B5

The Fibromyalgia Therapeutics Market was valued at USD 3.85 billion in 2025 and is projected to grow to USD 4.04 billion in 2026, with a CAGR of 5.66%, reaching USD 5.66 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.85 billion
Estimated Year [2026] USD 4.04 billion
Forecast Year [2032] USD 5.66 billion
CAGR (%) 5.66%

An in-depth introduction to the evolving fibromyalgia therapeutics landscape highlighting clinical complexity, treatment gaps, and strategic priorities

Fibromyalgia remains a clinically complex syndrome characterized by chronic widespread pain, fatigue, sleep disturbances, and cognitive symptoms that collectively drive significant functional impairment for patients and stress for care systems. Clinical heterogeneity and overlapping comorbidities such as mood disorders and chronic pain syndromes complicate diagnosis and therapeutic selection, which in turn elevates the importance of individualized care pathways and multi-modal management strategies. In practice, clinicians balance symptomatic pharmacologic options with non-pharmacologic interventions while seeking to minimize adverse effects and polypharmacy risks.

At the same time, evolving science has sharpened attention on central sensitization, neuroimmune interactions, and the role of dysregulated neurotransmission as targets for therapeutic innovation. Consequently, researchers and developers are redirecting efforts toward mechanism-aware candidates, repurposed agents with robust safety profiles, and adjunctive platforms that complement traditional pharmacotherapy. From a commercial perspective, stakeholders must reconcile clinical complexity with payer expectations and distribution realities, while ensuring that patient-reported outcomes and quality-of-life improvements are demonstrably integrated into product value propositions.

As the field moves forward, coordinated strategies that align clinical evidence generation, patient engagement, and stakeholder alignment will be essential for translating therapeutic promise into meaningful improvements in care delivery and patient functioning.

Transformative shifts reshaping fibromyalgia treatment through mechanism-focused therapeutics, digital care, adaptive clinical trials, and evolving payer engagement

The last several years have produced a series of transformative shifts that are changing how fibromyalgia therapeutics are developed, evaluated, and delivered. Scientific advances are moving the emphasis from broad symptomatic management to pathway-specific interventions informed by neurobiology, while adaptive trial designs and enriched enrolment strategies are accelerating the ability to test mechanism-based hypotheses in clinically relevant populations. Simultaneously, the rise of digital therapeutics and remote monitoring tools is expanding the portfolio of non-pharmacologic interventions that can be combined with drug therapies to deliver holistic care.

Regulatory agencies and payers are also evolving their expectations, increasingly focusing on patient-centric endpoints, real-world evidence, and outcomes that capture functional improvements rather than isolated symptom reduction. This shift has incentivized sponsors to design trials with composite measures and to engage early with payers to align on acceptable evidence packages. In parallel, advances in biomarkers and phenotyping are enabling more precise patient segmentation, which helps reduce heterogeneity in trial populations and improves signal detection for targeted therapeutics.

Taken together, these shifts create new opportunities for innovators to differentiate through evidence, for clinicians to personalize regimens, and for health systems to integrate multimodal care, but they also raise the bar for evidentiary rigor, cross-stakeholder coordination, and commercialization planning.

Evaluating how United States tariff measures in 2025 may reshape supply chains, procurement decisions, and development strategies for fibromyalgia therapeutics

Policy interventions such as tariff adjustments can exert material effects on the operational and strategic calculus for therapeutic development and deployment, and the United States tariff measures implemented in 2025 represent a notable variable for stakeholders in the fibromyalgia therapeutics ecosystem. These measures influence the cost and availability of active pharmaceutical ingredients, specialized excipients, medical devices used for neuromodulation or delivery, and laboratory reagents necessary for biomarker assays. As a result, sponsors and manufacturers must re-evaluate sourcing strategies and inventory practices to manage potential supply-chain volatility.

Moreover, procurement processes in hospitals and integrated delivery networks may shift in response to changed landed costs for imported components, prompting contract renegotiations and a renewed focus on supplier diversity. At the same time, manufacturers that rely on global contract manufacturing and international R&D partnerships may need to adjust operational footprints, either by identifying alternative suppliers or by increasing domestic capabilities to mitigate tariff exposure. These strategic responses have implications for product timelines, cost structures, and partner selection.

Importantly, the tariff environment also affects the competitive dynamics between branded and generic alternatives, since cost pressures can alter formulary positioning and negotiations with payers. Consequently, industry participants must adopt a proactive posture that incorporates scenario planning, supplier audits, and cross-functional coordination to preserve supply continuity and maintain alignment with clinical and commercial strategies.

Segmentation insights across drug class dynamics, administration routes, distribution channels, and end users to guide clinical and commercial decisions

Insights drawn from segmentation analysis reveal how clinical, commercial, and operational choices intersect across multiple axes that define the fibromyalgia therapeutics ecosystem. Based on drug class, the landscape encompasses Anticonvulsants, Selective Serotonin Reuptake Inhibitors, Serotonin And Norepinephrine Reuptake Inhibitors, and Tricyclic Antidepressants; within those categories, Anticonvulsants are further characterized by branded and generic options, and the same branded-versus-generic dynamic applies to Selective Serotonin Reuptake Inhibitors, Serotonin And Norepinephrine Reuptake Inhibitors, and Tricyclic Antidepressants, which directly affects lifecycle planning and price competitiveness.

Based on route of administration, products are evaluated in the contexts of Oral, Parenteral, and Topical delivery, each route offering distinct adherence profiles, formulation challenges, and opportunities for differentiation, particularly when formulation science or novel delivery devices can drive superior tolerability or targeted pharmacokinetics. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy pathways each present unique contracting, inventory, and patient-access considerations; the growth of e-commerce and specialty fulfillment has begun to reshape dispensing behavior and patient convenience expectations.

Finally, based on end user, therapy utilization varies across Home Care, Hospital, and Specialty Clinics, with home-based management and remote monitoring increasingly prominent for chronic care pathways, while hospitals and specialty clinics continue to anchor acute interventions, diagnostics, and multidisciplinary care. Synthesizing these segmentation lenses supports targeted clinical development, pricing strategies, and channel-specific commercialization plans.

Regional insights on regulatory regimes, clinical adoption, reimbursement models, and operational priorities across global territories for fibromyalgia treatment

Regional dynamics materially influence development priorities, access strategies, and commercialization pathways for fibromyalgia therapeutics, and a regionally calibrated approach is essential. In the Americas, regulatory frameworks and payer negotiations emphasize outcomes and pharmacoeconomic assessments, while innovation hubs and established contract manufacturing networks support rapid product iteration and supply chain resilience. The Americas also exhibit strong uptake of digital health solutions and patient advocacy momentum, which can accelerate enrollment in decentralized trials and adoption of integrated care pathways.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and reimbursement environments necessitate differentiated launch sequencing and bespoke value dossiers; pricing pressures in some European markets contrast with pockets of rapid adoption in specialty care settings, and the region's diverse healthcare architectures demand localized evidence generation and stakeholder engagement. Meanwhile, Asia-Pacific presents a mixed landscape where rapid clinical trial activity, growing domestic manufacturing capacity, and varied payer systems create both opportunities and complexities for market entry. In many Asia-Pacific markets, strategic partnerships with regional developers and local regulatory navigation are critical to securing access.

Across regions, cross-border collaboration, tailored payer dialogues, and adaptive evidence generation strategies enable sponsors to align clinical programs with local standards of care and reimbursement expectations while preserving global roadmap consistency.

Corporate and competitive insights on how innovators, specialty developers, contract manufacturers, and digital vendors shape fibromyalgia care strategies

Corporate positioning in the fibromyalgia therapeutics arena reflects an interplay between innovation-driven developers, specialty biotech ventures, contract manufacturing organizations, and emerging digital health vendors. Innovators are concentrating on differentiated mechanisms and improved tolerability profiles to achieve clinical differentiation, while specialty developers and platform companies pursue adjunctive approaches that can be combined with pharmacotherapy to address multidimensional symptom burden. Contract manufacturers and CDMOs are central to scaling complex formulations and ensuring supply reliability, and their capabilities increasingly factor into partner selection and contingency planning.

Digital vendors are partnering with clinical teams to embed remote monitoring, patient-reported outcome capture, and behavioral interventions into care pathways, which can strengthen value propositions to payers and providers. Across the value chain, strategic alliances, licensing deals, and selective M&A activity are common tactics to accelerate access to complementary assets, expand geographic reach, or acquire manufacturing capacity. At the same time, lifecycle management tactics such as new formulations, targeted indications, and enhanced labeling are being used to sustain commercial momentum in the face of generic competition.

To compete effectively, corporate leaders must synchronize R&D priorities with commercialization and access strategies, ensure rigorous evidence generation, and establish flexible manufacturing and distribution arrangements that can respond to regional and policy-driven disruptions.

Actionable recommendations for industry leaders to prioritize supply resilience, evidence-based development, payer alignment, and patient-centric commercialization approaches

Industry leaders should adopt a multi-pronged approach that strengthens supply resilience, advances evidence generation, and centers patient experience in commercialization plans. First, fortify supply chains by diversifying supplier bases for critical APIs and components, investing in strategic inventory buffers, and conducting regular supplier risk assessments to anticipate procurement disruptions. Second, prioritize development programs that integrate patient-reported outcomes and functional endpoints, use adaptive or enrichment trial designs where appropriate, and plan early interactions with regulators and payers to align on acceptable evidence packages.

Third, expand value propositions by pairing pharmacologic candidates with digital therapeutics, behavioral supports, or delivery innovations that improve adherence and functional outcomes, thereby enhancing the product's clinical and economic story. Fourth, strengthen payer engagement through outcomes-based contracting pilots, real-world evidence partnerships, and health economic modeling that clearly demonstrates the therapeutic's impact on utilization, quality of life, and total cost of care. Finally, invest in targeted commercial strategies that reflect segmentation realities: tailor messaging and channel approaches for hospital procurement, online pharmacy distribution, retail access, and specialty clinic relationships, and equip field teams with evidence-based tools to articulate differentiated value.

Taken together, these actions help organizations mitigate operational risks, accelerate adoption, and align therapeutic development with the needs of patients and health systems.

Detailed research methodology explaining data sources, expert engagements, real-world evidence techniques, and analytical rigor applied to fibromyalgia insights

The research underpinning these insights employed a mixed-methods design that triangulated qualitative expert input with quantitative evidence sources and document analysis to ensure analytical rigor and relevance. Primary research included structured interviews with clinical key opinion leaders, formulary decision makers, procurement specialists, and developers with active programs in fibromyalgia, providing perspective on real-world treatment patterns, evidence expectations, and operational constraints. Secondary sources comprised peer-reviewed clinical literature, regulatory filings, trial registries, and available public repositories of clinical and safety data to contextualize mechanistic and efficacy signals.

Supplementing these sources, real-world evidence techniques were applied where possible to interpret treatment utilization patterns and care pathways, and commercial intelligence informed assessments of distribution and channel dynamics. Analytical methods emphasized cross-validation across sources and sensitivity to regional regulatory nuances. Limitations of the methodology include variability in publicly available data granularity for certain therapeutic classes and the evolving nature of policy measures that can affect supply chain and reimbursement landscapes.

To support decision making, the methodology prioritized transparency regarding assumptions, provided appendices detailing source lists and interview profiles, and recommended ongoing evidence updates as new clinical and policy developments emerge.

Conclusive synthesis emphasizing integrated clinical, commercial, and policy actions to accelerate meaningful improvements in fibromyalgia patient care outcomes

In conclusion, the fibromyalgia therapeutics landscape is at an inflection point characterized by deeper mechanistic understanding, evolution in evidence expectations, and shifting operational dynamics driven by policy and supply considerations. Effective responses require aligning therapeutic development with patient-centered endpoints, investing in complementary digital and behavioral solutions, and maintaining supply chain agility to withstand policy-induced disruptions. Clinicians, payers, and developers must collaborate to define meaningful outcome measures and to design evidence-generation plans that support both regulatory approval and payer acceptance.

Strategically, organizations that integrate clinical differentiation, robust real-world evidence strategies, and tailored regional approaches will be best positioned to navigate competitive pressures and access constraints. Operational readiness-manifested through diversified sourcing, manufacturing flexibility, and proactive payer engagement-will be equally critical to sustaining product availability and value realization. Ultimately, delivering improved patient outcomes will depend on coordinated action across R&D, commercial, regulatory, and health system stakeholders, with an emphasis on transparent evidence, measurable functional benefits, and scalable care models.

Stakeholders who adopt these integrated approaches can more effectively translate therapeutic innovation into tangible improvements for patients living with fibromyalgia.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Fibromyalgia Therapeutics Market, by Drug Class

  • 8.1. Anticonvulsants
    • 8.1.1. Branded
    • 8.1.2. Generic
  • 8.2. Selective Serotonin Reuptake Inhibitors
    • 8.2.1. Branded
    • 8.2.2. Generic
  • 8.3. Serotonin And Norepinephrine Reuptake Inhibitors
    • 8.3.1. Branded
    • 8.3.2. Generic
  • 8.4. Tricyclic Antidepressants
    • 8.4.1. Branded
    • 8.4.2. Generic

9. Fibromyalgia Therapeutics Market, by Route Of Administration

  • 9.1. Oral
  • 9.2. Parenteral
  • 9.3. Topical

10. Fibromyalgia Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Fibromyalgia Therapeutics Market, by End User

  • 11.1. Home Care
  • 11.2. Hospital
  • 11.3. Specialty Clinics

12. Fibromyalgia Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Fibromyalgia Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Fibromyalgia Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Fibromyalgia Therapeutics Market

16. China Fibromyalgia Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Amgen Inc.
  • 17.7. Amicus Therapeutics
  • 17.8. Astellas Pharma Inc
  • 17.9. AstraZeneca plc
  • 17.10. Bayer AG
  • 17.11. Biogen Inc.
  • 17.12. BioMarin Pharmaceutical Inc
  • 17.13. C.H. Boehringer Sohn AG & Co. KG
  • 17.14. Eli Lilly and Company
  • 17.15. Gilead Sciences, Inc.
  • 17.16. GlaxoSmithKline (GSK)
  • 17.17. Jazz Pharmaceuticals plc
  • 17.18. Johnson & Johnson Services, Inc.
  • 17.19. Kyowa Kirin Co, Ltd
  • 17.20. Merck & Co., Inc.
  • 17.21. Novartis AG
  • 17.22. Pfizer inc.
  • 17.23. Regeneron Pharmaceuticals, Inc.
  • 17.24. Roche Holding AG
  • 17.25. Sanofi S.A.
  • 17.26. Sarepta Therapeutics, Inc.
  • 17.27. Takeda Pharmaceutical Company
  • 17.28. Teva Pharmaceutical Industries Ltd.
  • 17.29. The Bristol-Myers Squibb Company
  • 17.30. Vertex Pharmaceuticals Incorporated
  • 17.31. Viatris inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 160. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 162. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 187. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 188. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 189. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 198. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)